For the quarter ended December 2024, Kenvue (KVUE) reported revenue of $3.66 billion, down 0.1% over the same period last year. EPS came in at $0.26, compared to $0.31 in the year-ago quarter.
The reported revenue represents a surprise of -2.94% over the Zacks Consensus Estimate of $3.77 billion. With the consensus EPS estimate being $0.26, the company has not delivered EPS surprise.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Kenvue performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Self Care: $1.57 billion versus $1.59 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change.
- Net Sales- Essential Health: $1.08 billion versus the three-analyst average estimate of $1.17 billion. The reported number represents a year-over-year change of -4.1%.
- Net Sales- Skin Health and Beauty: $1.01 billion compared to the $1.02 billion average estimate based on three analysts. The reported number represents a change of +1% year over year.
- Adjusted Operating Income- Self Care: $481 million versus the two-analyst average estimate of $593.82 million.
- Adjusted Operating Income- Essential Health: $248 million versus the two-analyst average estimate of $81.11 million.
- Adjusted Operating Income- Skin Health and Beauty: $105 million versus $190.78 million estimated by two analysts on average.
Shares of Kenvue have returned -1.7% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Kenvue Inc. (KVUE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
